Daewoong Pharmaceutical Unveils Nabota and Medical Aesthetic Portfolio at WeSWAM 2025
(Jakarta, May 26th, 2025)
Daewoong Pharmaceutical has introduced its flagship botulinum toxin product, Nabota, along with its medical aesthetic portfolio to healthcare professionals in Indonesia.
Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee), in partnership with CnG Bio Indonesia(CBI), participated in the ‘2025 WeSWAM’ conference held at El Royale Hotel in Bandung, Indonesia, from April 25 to 27, 2025.
The 2025 WeSWAM, one of the regional events in the series of Indonesia’s largest aesthetic medicine conference SWAM, was held in West Java near Jakarta.
Organized by the Indonesian Society of Aesthetic Medicine (PERDESTI), SWAM (Seminar & Workshop in Aesthetic Medicine) is the largest international aesthetic medicine conference in Indonesia, held five times a year across major cities and attracting over 2,000 medical professionals annually.
The 2025 WeSWAM focused on practical training, peer networking, and the exchange of clinical experiences. This year’s event gathered approximately 300 medical professionals, 14 speakers, and 31 sponsors to share insights on the latest trends and hands-on techniques in aesthetic medicine.
At its dedicated exhibition booth, Daewoong announced the official launch of Nabota in Indonesia and showcased CBI’s medical aesthetic portfolio, including the HA filler brand ‘DCLASSY’, absorbable thread ‘DOOTH’, PDO (Polydioxanone) thread ‘LUXX’, and the calcium hydroxyapatite (CaHA)-based skin booster ‘Facetem’.
In particular, Daewoong actively promoted its global expert training program, DEEP (Daewoong Medical-AEsthetic Expert Program). DEEP is a global education initiative that brings together Daewoong’s extensive expertise in medical aesthetics. It invites aesthetic medicine professionals to participate in in-depth lectures and hands-on training sessions that can be immediately applied in clinical practice, along with academic exchanges that facilitate the sharing of insights among medical professionals.
Nabota is a premium botulinum toxin produced using Daewoong’s HI-PURE™ Technology, patented in Korea and the U.S., and a vacuum-drying process, resulting in a high-purity product (over 98% of 900kDa toxin) with rapid onset of action and minimized risk of inactive toxin formation, which can cause resistance.
Nabota has received regulatory approvals in 69 countries, including the U.S. FDA, EMA, Health Canada, and Indonesia’s BPOM, and has formed partnerships in over 80 countries—solidifying its rapidly growing global presence.
Jun-Soo Yun, Head of Daewoong’s Nabota Business Division, stated, “Through these activities, Daewoong Pharmaceutical aims to establish itself as a leading brand for combination aesthetic procedures in Asia. Our long-term goal is to become Asia’s No.1 integrated aesthetic solution provider—delivering innovative solutions and patient safety through science-backed products and professional education.”
Chang-woo Ha, the Head of Aesthetic Business for Daewoong Group in Korea and Indonesia, added, “We have officially launched our customized combination treatment portfolio and the DEEP expert training program with Daewoong Pharmaceutical. Through the DEEP program, we will share our expertise based on a diverse portfolio and aim to lead a healthy and in-depth medical aesthetics market.”
Starting with WeSWAM, Daewoong Pharmaceutical plans to continue its comprehensive DEEP education roadmap with webinars in May, AMUSE workshops and lectures in June, and a formal product launch symposium in July. The company aims to provide advanced aesthetic treatments to Indonesian medical professionals and, under the vision “Move to NEW GEN” strengthen both brand awareness and expertise as a next-generation leader in the local aesthetics industry.
# # #
